Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

The company reckons it’s got what it takes to hit the right member of the FGFR family.

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.

ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.

Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.